Analysis and protocolization of rasburicase use in patients with hematologic neoplasms;Análisis y protocolización de la utilización de rasburicasa en pacientes con neoplasias hematológicas

Farmacia Hospitalaria

Volumn 30, Issue 2, 2006, Pages 92-98

  Llinares, F ^a   Burgos, Amparo ^a,b   Fernandez P ^a   Villarrubia, B ^a   Ferrandis, P ^a   Ordovas J P ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b NONE   (Spain)

Author keywords

Acute leukemia; Cost effectiveness; Hyperuricemia; Lymphoma; Rasburicase; Tumoral lysis syndrome

Indexed keywords

CALCIUM; CREATININE; LACTATE DEHYDROGENASE; PHOSPHATE; POTASSIUM; RASBURICASE; URIC ACID;

ADULT; AGED; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG DOSE REGIMEN; DRUG USE; FEMALE; HEMODIALYSIS; HUMAN; HYPERURICEMIA; LEUKEMIA; LEUKOCYTE COUNT; LYMPHOMA; MALE; PHARMACY; POTASSIUM BLOOD LEVEL; RETROSPECTIVE STUDY; REVIEW; TERTIARY HEALTH CARE; TREATMENT DURATION;

EID: 33745797679     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(06)73953-8     Document Type: Article

References (22)

1. Annemans L, Moeremans K, Lamotte M, García-Conde J, Berg H, Myint H, et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumor lysis syndrome in haematological cancer patients. Support Care Cancer 2003; 11: 249-57.
2. Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL. Acute tumor lysis syndrome. A review of 37 patients with Burkitt lymphoma. Am J Med 1980; 68: 486-91.
3. Stapleton FB, Strother DR, Roy S, Wyatt RJ, Mc Kay CP, Murphy SB. Acute renal failure at the onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics 1988; 82: 863-9.
4. Jeha S. Tumor lysis syndrome. Semin Hematol 2001; 38: 4-8.
5. Sallan S. Management of acute tumor lysis syndrome. Semin Oncol 2001; 28: 9-12.
6. Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, Van der Vorst MM. Alkalinization and the tumor lysis syndrome. Med Pediatr Oncol 1998; 31: 27-8.
7. Koduri PR. Acute tumor lysis syndrome and alkali therapy. Am J Med 1995; 98: 417.
8. Zyloric. Summary of product characteristics: http://emc.vhn.net/eMC/ assets/c/html/Displaydoc.asp?document ID=4565
9. Ribeiro RC, Pui CH. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. Clin Lymphoma 2003; 3: 225-32.
10. Pui CH, Jeha S, Irwin D, Camilla B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001; 15: 1505-9.
11. Yeldandi AV, Yeldandi V, Kumar S, Murthy CV, Wang XD, Alvares K, et al. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene 1991; 109: 281-4.
12. Coiffier B, Maunier M, Bologna S, Fermé C, Tilly H, Sonet A, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003; 21: 4402-6.
13. Lim E, Bennett P, Beilby J. Sample preparation in patients receiving uric acid oxidase (rasburicase) therapy. Clin Chem 2003; 49: 1417-9.
14. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001; 19: 697-704.
15. Bosly A, Sonet A, Pinketon CR, McCowage, Bron D, Sanz MA, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003; 98: 1048-54.
16. Pui CH. Urate oxidase in the prophylaxis or treatment of hyperuricemia: The United States experience. Semin Hematol 2001; 38: 13-21.
17. Rasburicase (Elitek) for hyperuricemia. Med Lett Drugs Ther 2002; 44: 96-7.
18. Goldman S. Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies. Expert Rev Anticancer Ther 2003; 3: 429-33.
19. Hummel M, Buchheidt D, Reiter S, Bergmann J, Hofheinz R, Hehlmann R. Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome. Leukemia 2003; 17: 2542-4.
20. Lee A, Li C, So K, Chan R. Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother 2003; 37: 1614-7.
21. Arnold T, Reuter J, Delman B, Shanholtz C. Use of single-dose rasburicase in a obese female. Ann Pharmacother 2004; 38: 1428-31.
22. Holdsworth MT. Role of iv allopurinol and rasburicase in tumor lysis syndrome. Am J Health-Syst Pharm 2003; 60: 2213-22.